Page 1

Q1 Alligator Bioscience AB ( publ ) Interim report January - March 2021 High activity during the first quarter ALLIGATOR bioscience Significant events January - March Pipeline ⚫ New preclinical data were released in an abstract for a poster presentation at the AACR Annual Meeting 2021 , demonstrating that mitazalimab synergizes with chemotherapy . Company ⚫ Søren Bregenholt was appointed as new CEO to strengthen Alligator's business development activities and clinical progress on an international level . Oversubscribed rights issue generated proceeds of SEK 86 million before transaction costs . Significant events after the end of the period Alligator and the US biopharmaceutical company MacroGenics entered into a joint research collaboration to develop Neo - X - Prime ™ , next generation immune oncology therapy building on Alligator's CD40 expertise . The Annual General Meeting was postponed to June 1 , 2021 . ⚫ The Nomination Committee proposed that the Annual General Meeting 2021 re - elects Anders Ekblom and Graham Dixon as board members , and that Hans - Peter Ostler , Eva Sjökvist Saers and Veronica Wallin are elected as new board members . Financial summary January - March 2021 Net sales , SEK 0.6 million ( 0 ) • Operating result , SEK - 32.5 million ( -44.9 ) ⚫ Result for the period , SEK -32.7 million ( -42.9 ) • Earnings per share before and after dilution , SEK -0.38 ( -0.6 ) ⚫ Cash flow for the period , SEK 40.4 million ( 108.4 ) Cash and cash equivalents , incl . interest - bearing securities , SEK 143.7 million ( 103.3 ) DISCOVERY The information was submitted for publication at 8:00 a.m. CET on April 27 , 2021. For contact details , see page 13 . PRECLINICAL 1 | Alligator Bioscience AB | Interim report January - March 2021 CLINICAL PHASE I ALG.APV - 527 " So far , 2021 has been characterized by high activity , with a research collaboration that validates our Discovery concept Neo - X - PrimeTM , and good progress of our clinical programs , with ATOR - 1017 and mitazalimab entering clinical efficacy studies this year . " Malin Carlsson Interim CEO Alligator Bioscience AB ( publ ) CLINICAL PHASE II ATOR - 1017 ATOR - 1015 Mitazalimab AC101 Introduction